Join the Methylphenidate group to help and get support from people like you.
Methylphenidate News
Big Drop in U.S. Kids, Teens Misusing Prescription Meds
WEDNESDAY, July 24, 2024 – Misuse of illicit prescription drugs is falling dramatically among U.S. high school students, a new study says. The percentage of seniors who say they’ve misused p...
ADHD Meds Tied to Heart Damage in Young Adult Users
WEDNESDAY, March 27, 2024 – ADHD stimulant medications like Ritalin or Adderall appear linked to a heightened risk for cardiomyopathy (a weakening of the heart muscle), and the risk grows with time,...
In Utero Rx Stimulant Exposure Not Tied to Later Neurodevelopmental Issues
THURSDAY, Feb. 1, 2024 --Amphetamine/dextroamphetamine and methylphenidate exposure in utero does not appear to increase the risk for childhood neurodevelopmental disorders, according to a study...
Seniors With ADHD Face Higher Car Crash Risk
WEDNESDAY, Oct. 4, 2023 – While studies of ADHD and driving usually target teens, a new one focused on seniors found they have a significantly higher risk of car crashes. Older adults with...
FDA Medwatch Alert: FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions
What safety concern is FDA announcing? To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, the U.S. Food and Drug Administration (FDA) is requiring...
FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD
STAMFORD, Conn.--(BUSINESS WIRE) March 01, 2019 --Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR...
FDA Approves Jornay PM (methylphenidate) Extended-Release Capsules for Attention Deficit Hyperactivity Disorder (ADHD)
GEORGE TOWN, Cayman Islands--(BUSINESS WIRE)August 09, 2018 --Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”) a wholly owned subsidiary of Highland Therapeutics Inc. (“Highland”) announc...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Pfizer Receives FDA Approval for QuilliChew ER (methylphenidate hydrochloride) Extended-Release Chewable Tablets
Monday, December 7, 2015 - Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer now offers two different products for the...
FDA Medwatch Alert: Daytrana Patch (methylphenidate transdermal system): Drug Safety Communication - Permanent Skin Color Changes
ISSUE: FDA is warning that permanent loss of skin color may occur with use of the Daytrana patch (methylphenidate transdermal system) for Attention Deficit Hyperactivity Disorder (ADHD). FDA added a...
FDA Medwatch Alert: Methylphenidate ADHD Medications: Drug Safety Communication - Risk of Long-lasting Erections
ISSUE: FDA is warning that methylphenidate products (including Concerta, Daytrana, Focalin/Focalin XR, Metadate CD/Metadate ER, Methylin/Methylin ER, Quillivant XR, Ritalin/Ritalin LA/Ritalin SR),...
NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR for Once-Daily Treatment of ADHD
CUPERTINO, Calif., Oct. 1, 2012 /PRNewswire/ – NextWave Pharmaceuticals, an emerging specialty pharmaceutical company, announced FDA approval of Quillivant XR (methylphenidate hydrochloride) for...
FDA Approves Daytrana (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents
DUBLIN and PHILADELPHIA, July 6 /PRNewswire-FirstCall/ – Shire plc , the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana...
Further information
Related condition support groups
Attention-Deficit Hyperactivity Disorder (ADHD), Narcolepsy, Depression, Fatigue, Weight Loss (Obesity / Overweight)